



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

| | |
|---------------------------------|--|
| Reagent: | Anti-HIV-1 gp120 Monoclonal (VRC03) |
| Catalog Number: | 12032 |
| Lot Number: | 120158 |
| Release Category: | C |
| Provided: | 500 µg of purified antibody, lyophilized. Add 125 µl ddH ₂ O to achieve 1x PBS. |
| Description: | HIV-1 envelope monoclonal antibody directed towards the CD4-binding site of HIV-1 gp120. Purified by protein A sepharose column chromatography. |
| Host: | Human |
| Titer: | ELISA (BaL gp120 protein), 1:10,000 |
| Special Characteristics: | <p>Broadly neutralizing HIV-1 antibody; active against all major subtypes. No cross-reactivity against host self or other antigens.</p> <p>Suggested working dilutions: ELISA, 5 µg/mL; HIV-1 neutralization, 50 µg/mL.</p> <p>Purity: >95%</p> |
| Recommended Storage: | -80°C |
| Contributor: | Xueling Wu, Zhi-Yong Yang, Yuxing Li, Gary Nabel, John Mascola |
| Isotype: | IgG ₁ , kappa |

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References:

Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. *Science* 2010;329(5993):856-61.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 gp120 MAb (VRC03), from Dr. John Mascola." Also include the reference cited above in any publications.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact: The Office of Technology Development, NIAID, 6610 Rockledge Drive, Suite 2800, MSC 6606, Bethesda, MD, 20892-6606, Tel: 301-496-2644, Fax: 301-402-7123, before the reagent can be released.

Patent Pending

Last Updated

March 24, 2016

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.